June 2019

Nasdaq: ALDX

©Aldeyra Therapeutics, Inc. 2019

**JEFFERIES 2019 HEALTHCARE CONFERENCE** 

# Innovating Transformative Therapies

## Disclaimers and Forward-Looking Statements

This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra's possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, trends, the structure, timing and success of Aldeyra's planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "plan" or similar expressions and the negatives of those terms.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aldeyra's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect Aldeyra's current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including the development, clinical and regulatory plans or expectations for Aldeyra's product candidates and Aldeyra's continuing review and quality control analysis of clinical data. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements are described in Aldeyra's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as Aldeyra's subsequent filings with the Securities and Exchange Commission. All of Aldeyra's development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, and other factors that could delay the initiation, completion, or reporting of clinical trials.

In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this presentation is provided only <u>as of June 6, 2019</u>, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.



### **Our Mission**

## Developing Next-Generation Medicines to Improve the Lives of Patients with Immune-Mediated Diseases



aldeyra

Suffer from some form of immune-mediated disease, and incidence is increasing



Disease control elusive despite existing therapies, and thus novel approaches are needed

Source: Lerner, Jeremias, and Matthias, International Journal of Celiac Disease, vol. 3, no. 4 (2015): 151-155;

Shurin and Smolkin, Advances in Experimental Medicines and Biology 601:3-12, 2007; Kuek et al, Postgraduate Medical Journal 83(978): 251-260, 2007.

## Deep and Innovative Pipeline Focused on Immune-Mediated Diseases

Disease Area	Compound	[Mechanism]	Indication	Preclinical	Phase 1	Phase 2	Phase 3	<b>Next Anticipated Milestone</b>
Ocular Diseases	Reproxalap	[RASP]	Dry Eye Disease			✓ ✓		
			Allergic Conjunctivitis			✓ ✓	$\checkmark$	
			Noninfectious Anterior Uveitis			✓		Phase 3 results H2 2019
	ADX-2191	[DHFR]	Proliferative Vitreoretinopathy					Phase 3-Part 1 initiation H2 2019
	ADX-103	[RASP]	Retinal Disease					Phase 1/2 initiation 2020
	Undisclosed		Ocular Inflammation	Research	h Collaboratio	on (undisclosed	d)	
Systemic Diseases	Reproxalap	[RASP]	Sjögren-Larsson Syndrome			✓	Ph	ase 3-Part 1 completion H2 2019
	ADX-1612	[ECHP]	PTLD					Phase 2 initiation 2019
			Mesothelioma			$\checkmark$		Phase 2 initiation 2019
			Ovarian Cancer			Investigat	tor-Sponsore	d Trial
	ADX-629	[RASP]	Autoimmune Disease					Phase 1 initiation H2 2019
	ADX-1615	[ECHP]	Autoimmune Disease / Cancer					
	Undisclosed	[RASP]	Systemic Inflammatory Disease	Research	h Collaboratio	on Janssen		
aldeyra			sm = Reactive Aldehyde Species Inhibitor sm = Dihydrofolate Reductase Inhibitor			trial data reporte		4

ECHP Mechanism = Epichaperome Inhibitor PTLD = Post-Transplant Lymphoproliferative Disorder

Trial initiations contingent on funding, regulatory review, and other factors

### Our Lead Programs May Offer Potential Benefits Over Standard of Care

**Current Standard** Pricina **Drug Candidate Potential Late Stage Programs** Benchmarks† and Dev. Stage Competitive Advantages † of Care Ocular Diseases Reproxalap: Rapid onset, broad activity, Dry Eye Disease Xiidra®, Restasis® reduction in itch Phase 3 \$500-550 per month Allergic Reproxalap: (dry eye disease pricing) Non-drying, durable activity; **Antihistamines** Conjunctivitis Responder superiority vs. vehicle Phase 3 Noninfectious Reproxalap: No expected risk of glaucoma or other corticosteroid \$1,500 per regimen Corticosteroids **Anterior Uveitis** Phase 3 toxicities (to treat one flare) **Proliferative** ADX-2191: Clinically demonstrated activity; \$30,000 per course None Vitreoretinopathy Phase 3 Currently no FDA- or EMA-approved therapy (avg. cost of surgeries) (repeat surgeries) Systemic Diseases Sjögren-Larsson \$200,000 - \$400,000 per Reproxalap: None Clinically demonstrated activity; **Syndrome** Phase 3 Currently no FDA- or EMA-approved therapy (manage symptoms) vear

aldeyra

<sup>&</sup>lt;sup>†</sup>Pending clinical data, regulatory discussions, payor negotiations, competition, potential legislative changes, and other factors, which may not be in Aldeyra's control. Preliminary assumptions are subject to change.

June 2019

Nasdaq: ALDX

©Aldeyra Therapeutics, Inc. 2019

- DRY EYE DISEASE
- ALLERGIC CONJUNCTIVITIS
- NONINFECTIOUS ANTERIOR UVEITIS
- PROLIFERATIVE VITREORETINOPATHY

## Ocular Disease Area

### **Dry Eye Disease:**

## Persistently Disturbing Disease with Inadequate Therapy

### **Dry Eye Disease**

20 million or more adults in the U.S. suffer from DED



Current Rx options may require up to six weeks or longer to achieve even modest efficacy





Up to 75% of patients with DED are not satisfied with current prescription options



Up to 50% of patients treated for DED with current therapies fail and

### Reproxalap in DED



Early and consistent symptom and sign improvements in Phase 2b clinical trial



**Broad symptom and sign** improvements in Phase 2b clinical trial



Women are twice as likely to suffer from DED than men



discontinue




Significant negative quality of life impact

**Underserved Patient Population** 




Reproxalap

## Dry Eye Disease Symptom and Sign Endpoints Achieved in Phase 2b Clinical Trial



## Broad Pattern of Drug Activity Across Dry Eye Disease Symptoms and Signs Supports Differentiated Product Profile

### **Improvement Effect Size at Week 12**



Break-Up Time, and Osmolarity)

aldeyra

Improvement Effect size = Change from Baseline / Standard Deviation at Baseline Source: Reproxalap DED Phase 2b clinical trial results

## Adaptive Phase 3 Dry Eye Disease Clinical Program

### **Adaptive Phase 3 Program**




Confirm symptom and sign endpoints from Phase 2b trial



Confirm dosing regimen (QID vs. QID to BID taper)



Confirm sample size for subsequent trial



Adaptive design, co-primary endpoints, and innovative analysis strategy confirmed with FDA at EOP2 Meeting



## RENEW Trial Design in Dry Eye Disease Adaptive Phase 3 (Part 1) Clinical Trial Initiated April 2019

### Primary objective:

 Evaluate efficacy of reproxalap ophthalmic solution (0.25%) vs. vehicle to confirm dosing regimen and sample size for Part 2

#### Inclusion/exclusion criteria:

- Same as used for Phase 2b
- Moderate to severe dry eye disease


### Co-primary endpoints:

 Ocular dryness score (0-100mm VAS) and fluorescein nasal region staining

### Analysis strategy:

- Both co-primary endpoints will be assessed using Mixed Model Repeated Measures (MMRM) from week 2 to week 12
- Both co-primary endpoints will be assessed based on separate prespecified patient populations
  - Ocular dryness score (OD4SS): baseline score of > 3
  - Fluorescein nasal staining: baseline score ≥ 2

### Phase 3 Dry Eye Disease Clinical Trial: Part 1





June 2019

Nasdaq: ALDX

©Aldeyra Therapeutics, Inc. 2019

- DRY EYE DISEASE
- ALLERGIC CONJUNCTIVITIS
- NONINFECTIOUS ANTERIOR UVEITIS
- PROLIFERATIVE VITREORETINOPATHY

## Ocular Disease Area

## **Allergic Conjunctivitis:**

### A Common Disease with Unmet Medical Need

### **Allergic Conjunctivitis**



Up to 30 million of **AC sufferers** in the U.S. do not respond adequately to or are dissatisfied with antihistamines



Many AC patients make significant sacrifices due to lack of drug activity



Antihistamines are not effective in an estimated 24% of treated AC patients



AC can result in acute, intermittent, and chronic symptoms

AC patients experience symptoms throughout all decades of adult life



~2% of AC patients have severe symptoms and may be corticosteroid-dependent



Significant negative quality of life impact

**Underserved Patient Population** 

### Reproxalap

### Reproxalap in AC



Clinically significant and durable symptom response in Phase 3 clinical trial




Active in post-histaminic allergy, for which no drug is approved





## Novel Mechanism of Action has the Potential to Provide Differentiated Activity Versus Antihistamines




Reproxalap has the potential to be uniquely effective in post-histaminic allergy, which affects all allergic conjunctivitis patients



## Reproxalap Showed Greater and More Durable Clinical Responses vs. Vehicle Group in ALLEVIATE Phase 3 Clinical Trial

#### **Primary Endpoint**


Area Under the Curve: Ocular Itch Score (0-4) 10 to 60 Minutes After Allergen Challenge



Improvement in itch score over one hour after allergen exposure statistically greater for reproxalap vs. vehicle

### Key Secondary Endpoint

Probability of Two-Point Response: Ocular Itch Score (0-4)



Clinically significant response rate of reproxalap statistically higher than that of vehicle




SEM = Standard error of the mean

GEE = Generalized estimating equation analysis


## Reproxalap Showed Greater and More Durable Clinical Responses vs. Vehicle in Allergen Chamber Clinical Trial

#### Ocular Itch Score (0-100) During 3.5 Hours of Allergen Exposure



Statistically significant reduction in ocular itch vs. vehicle for more than three hours of exposure to allergen


#### Ocular Redness Score (0-4) During 3.5 Hours of Allergen Exposure



Statistically significant reduction in ocular redness vs. vehicle for more than three hours of exposure to allergen



## Allergic Conjunctivitis Phase 3 Clinical Program Design Elements





June 2019

Nasdaq: ALDX

©Aldeyra Therapeutics, Inc. 2019

- DRY EYE DISEASE
- ALLERGIC CONJUNCTIVITIS
- NONINFECTIOUS ANTERIOR UVEITIS
- PROLIFERATIVE VITREORETINOPATHY

## Ocular Disease Area

### **Noninfectious anterior uveitis:**

## A Serious Inflammatory Disease With Inadequate Current Therapy

### **Noninfectious Anterior Uveitis**

Reproxalap



Noninfectious anterior uveitis (NAU) is **the most common form of uveitis**, with an estimated 260,000 U.S. patients per year



~50% of NAU patients have **recurrent or chronic conditions** requiring multiple interventions per year



Corticosteroids are currently SOC and require monitoring due to serious toxicities



Prolonged usage may lead to **glaucoma**, **cataracts**, **corneal ulceration**, and other serious side effects

### Reproxalap


- A novel and differentiated approach to treat NAU
- Reduced anterior chamber cell count in a Phase 2 clinical trial, and was statistically non-inferior to corticosteroid treatment
- Safety and tolerability without intraocular pressure increase in a Phase 2 clinical trial
- SOLACE Phase 3 clinical trial results expected H2 2019



## Reproxalap Reduced Inflammation in Noninfectious Anterior Uveitis Phase 2 Clinical Trial

#### **Change from Baseline in Anterior Chamber Inflammatory Cell Grade**

ITT Population with Last Observation Carried Forward



Proportion Cured (Grade 0 = no inflammatory cells observed)						
Week 4 Grade 0	Percent of Subjects					
Reproxalap	53% (8/15)					
Corticosteroid	38% (5/13)					

Reproxalap was statistically non-inferior to corticosteroid in a noninfectious anterior uveitis Phase 2 clinical trial




Source: Reproxalap NAU Phase 2b clinical trial results

## Reproxalap Did Not Increase Intraocular Pressure in Noninfectious Anterior Uveitis Phase 2 Clinical Trial

#### **Change from Baseline in Intraocular Pressure (mmHg)**

Safety Population



Increase in intraocular pressure, which may lead to glaucoma, is a major corticosteroid toxicity that is not apparent with reproxalap




21

## SOLACE Trial Design in Noninfectious Anterior Uveitis Phase 3 Clinical Trial Initiated April 2017

#### Primary objective:

- Evaluate efficacy of reproxalap ophthalmic solution (0.5%) on anterior chamber cell count (ACC) vs. vehicle
- Inclusion highlights:
  - Acute endogenous NAU with onset of symptoms within the previous 2 weeks
  - 6-50 ACC in the study eye
  - Intraocular pressure <21</li>
- Dosing regimen:
  - Week 1 8x/day
  - Week 2 6x/day
  - Weeks 3-4 4x/day
  - Week 5 None
- Endpoints:
  - Time-to-cure (zero inflammatory cells in anterior chamber) without rescue
- Results expected to be announced H2 2019

#### **Phase 3 Noninfectious Anterior Uveitis Trial**





June 2019

Nasdaq: ALDX

©Aldeyra Therapeutics, Inc. 2019

- DRY EYE DISEASE
- ALLERGIC CONJUNCTIVITIS
- NONINFECTIOUS ANTERIOR UVEITIS
- PROLIFERATIVE VITREORETINOPATHY

## Ocular Disease Area

### **Proliferative vitreoretinopathy:**

## A Rare Sight-Threatening Retinal Disease With No Approved Therapies

### **Proliferative vitreoretinopathy**

**ADX-2191** 



PVR is a **rare disease**, with ~4,000 patients per year in the U.S. and nearly twice as many in Europe and Japan



Left untreated, retinal detachment due to PVR can progress to permanent blindness



No FDA- or EMA-approved therapy



Repeat surgery and subsequent vision loss currently the only possible course of action


#### **ADX-2191**

- A novel approach and potential therapeutic breakthrough in PVR treatment
- Granted U.S. orphan designation for the prevention of PVR
- Tolerability and reattachment success during study period demonstrated in Phase 1b open-label investigator sponsored clinical trial
- Adaptive Phase 3 clinical trial expected to initiate H<sub>2</sub> 2019



## ADX-2191 Reduced Recurrent Retinal Detachment in Investigator Sponsored Phase 1b Clinical Trial and in Additional In-Practice Use

### **Retinal Detachments Over Time by Patient**





RD = Retinal detachment PVR = Proliferative vitreoretinopathy SRF = Subretinal fluid

## **ADX-2191:** Adaptive Phase 3 (Part 1) Proliferative Vitreoretinopathy Clinical Trial Design\*

#### Primary objective:

 Evaluate efficacy of intravitreal ADX-2191 injections for prevention of recurrent retinal detachment due to proliferative vitreoretinopathy (PVR)

#### Design:

 Multi-center, non-masked, randomized, controlled, two- part, adaptive Phase 3 clinical trial

#### Inclusion highlights:

- Recurrent retinal detachment due to PVR, or
- Retinal detachment associated with open-globe trauma


#### Dosing regimen:

 At surgery, weekly (x8), and then every other week (x4) intravitreal ADX-2191 injections

#### Endpoint:

- Retinal re-detachments due to PVR requiring re-operation within 6 months:
  - 1. OCT demonstrating fovea-off retinal detachment
  - 2. Photographic documentation retinal detachment

#### Adaptive Phase 3 PVR Clinical Trial Design: Part 1





June 2019

Nasdaq: ALDX

©Aldeyra Therapeutics, Inc. 2019

SJÖGREN-LARSSON SYNDROME

## Systemic Disease Area

## Sjögren-Larsson Syndrome:

## A Rare RASP-Mediated Disease with No Approved Therapy

### Sjögren-Larsson Syndrome





SLS is a rare disease caused by an enzyme mutation (Fatty Aldehyde Dehydrogenase), with ~1,000 SLS patients in the U.S. and a greater number in Europe



Severe symptoms significantly impacts SLS patient and caregiver quality of life



No FDA- or EMA-approved therapy




Nonstop disease burden prevents normal patient/caregiver life, with hours devoted to managing painful scaling, monitoring, & care

### Reproxalap

- A novel approach and potential lifelong therapy to replace missing enzymatic activity in SLS
- Granted U.S. orphan designation for the treatment of congenital ichthyosis (primary symptom of SLS)
- Significantly reduced SLS ichthyosis in a randomized, vehiclecontrolled Phase 2 clinical trial
- RESET Part 1 Phase 3 clinical trial completion expected H2 2019



## Reproxalap Demonstrated Clinically Relevant and Consistent Activity in Phase 2 Clinical Trial



Over two months of treatment, ichthyosis improved consistently from moderate to mild disease

## RESET Trial Design in Sjögren-Larsson Syndrome Phase 3 Part 1 Clinical Trial Initiated July 2018

#### Primary objective:

 Evaluate efficacy of reproxalap topical dermal cream (1%) for the treatment of SLS associated ichthyosis

### Inclusion/exclusion highlights:

- Genetically confirmed diagnosis of SLS and at least 3 years of age or older
- Active ichthyosis grade <u>></u>2 on the VIIS scaling score
- No systemic or topical retinoids or other topical medications with in the past 30 days prior to baseline visit 1


#### · Dosing regimen:

- Weeks 1-12: 20% of Body Surface Area (BSA)
- Weeks 13-20: 40-45% of BSA
- Weeks 21-24: 90% of BSA

#### Endpoints:

- Baseline ichthyosis change in drug-treated subjects
- Safety / tolerability
- Completion expected H2 2019

### Phase 3 SLS-Ichthyosis Study: Part 1





June 2019

Nasdaq: ALDX

©Aldeyra Therapeutics, Inc. 2019

## Building The Future

## Our Value Proposition

Deep and Innovative Pipeline focused on immune-mediated diseases



commercialization

Solid Track Record of development success

\_\_ao\_\_ aldeyra

Large Market
Potential of late-stage
pipeline

**Solid Cash Position** 

Cash, cash equivalents and marketable securities were \$82.1 million as of March 31, 2019



### **Experienced Management Team and Board of Directors**

### **Management Team**

Todd Brady, M.D., Ph.D. President, CEO, & Director

Joshua Reed, M.B.A. **Chief Financial Officer** 

David Clark, M.D. **Chief Medical Officer** 

David McMullin, M.B.A. Chief Commercial Officer

Stephen Machatha, Ph.D. **SVP Technical Operations** 

















### **Board of Directors**

Richard Douglas, Ph.D. CHAIRMAN

Ben Bronstein, M.D.

Marty Joyce, M.B.A.

Gary Phillips, M.D.

Jesse Treu, Ph.D.

Neal Walker, D.O.

Todd Brady, M.D., Ph.D.

- 1. Acquired by Xanthus/Antisoma
- 2. Acquired by Schwarz/UCB
- 3. Acquired by Alexion
- Acquired by Takeda

Former SVP Corporate Development at Genzyme

Former CEO Peptimmune<sup>8</sup>

Former CFO of Serono USA

CEO OrphoMed

**Domain Associates** 

**CEO Aclaris Therapeutics** 

**CEO Aldeyra Therapeutics** 

- 5. Acquired by Ligand
- 6. Acquired by Merck
- 7. Acquired by Alexion
- 8. Acquired by Genzyme



## **Expected Development Milestones:**\*

### Novel Approaches to Address Immune-Mediated Disease

### **Ocular Diseases: Anticipated Milestones Systemic Diseases: Anticipated Milestones** Positive reproxalap ALLEVIATE Phase 3 clinical trial Reproxalap Sjögren-Larsson Syndrome RESET Phase 3results March 2019 Part 1 clinical trial completion H2 2019 Reproxalap dry eye disease RENEW Phase 3 clinical trial ADX-629 Phase 1 clinical trial initiation program initiation April 2019 H2 2019 followed by NASH and/or IBD Phase 2a Reproxalap noninfectious anterior uveitis ADX-1612 post-transplant lymphoproliferative disorder **SOLACE Phase 3 clinical trial results H2 2019** Phase 2 clinical trial initiation 2019 ADX-1612 mesothelioma Phase 2 clinical trial initiation ADX-2191 Proliferative Vitreoretinopathy Phase 3 clinical program initiation H2 2019 2019 Remaining clinical requirements for potential allergic conjunctivitis NDA to be confirmed



H<sub>2</sub> 2019

June 2019

Nasdaq: ALDX

©Aldeyra Therapeutics, Inc. 2019

**JEFFERIES 2019 HEALTHCARE CONFERENCE** 

# Innovating Transformative Therapies